2011
DOI: 10.3111/13696998.2011.605818 View full text |Buy / Rent full text
|
|

Abstract: In a real-world setting among T2DM patients who failed to achieve or sustain glycemic goal with OADs, initiation of GLA-P instead of EXE may be a more effective option because it was associated with greater treatment persistence, greater A1C reduction without a significantly higher rate of hypoglycemia, and similar healthcare costs.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
1
14
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
5

Relationship

4
1

Authors

Journals

1
14
0
Order By: Relevance
“…Treatment persistence was defined as patients remaining on the index insulin (insulin glargine for GLA-C and GLA-S, and insulin detemir for DET-C and DET-S) during the follow-up period without discontinuation after the index date [7, 8, 1820]. Study medication was considered discontinued if the prescription was not refilled within the expected time of medication coverage (the 90th percentile of the time, stratified by the metric quantity supplied, between first and second fills among patients with at least one refill).…”
Section: Methodsmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Treatment persistence was defined as patients remaining on the index insulin (insulin glargine for GLA-C and GLA-S, and insulin detemir for DET-C and DET-S) during the follow-up period without discontinuation after the index date [7, 8, 1820]. Study medication was considered discontinued if the prescription was not refilled within the expected time of medication coverage (the 90th percentile of the time, stratified by the metric quantity supplied, between first and second fills among patients with at least one refill).…”
Section: Methodsmentioning
“…Twenty-three prospective studies3557 and seven retrospective studies18,5863 compared GLP-1RAs with insulin products.…”
Section: Efficacy Of Glp-1ras Versus Other Glucose-lowering Therapiesmentioning
“…In fact, the 12 month persistence rates in the current study were higher than in similar previous Study medication was considered discontinued if the prescription was not refilled within the expected time of medication coverage, which was defined as the 90th, 75th or 50th percentile of the time between first and second fills among patients with at least one refill. studies based on pharmacy claims data 10,20,21 . Additionally, any difference in the proportion of pen users between groups (which is unobservable in our data) may diminish comparability.…”
Section: Study Limitationsmentioning